# FLI-1 Functionally Interacts with PIASxα, a Member of the PIAS E3 SUMO Ligase Family

Emile van den Akker, Sabine Ano, Hsiu-Ming Shih, Ling-Chi Wang, Martine Pironin, Jorma J. Palvimo, Noora Kotaja, Olivier Kirsh, Anne Dejean,

Jacques Ghysdael

► To cite this version:

Emile van den Akker, Sabine Ano, Hsiu-Ming Shih, Ling-Chi Wang, Martine Pironin, et al., FLI-1 Functionally Interacts with PIASxα, a Member of the PIAS E3 SUMO Ligase Family. Journal of Biological Chemistry, 2005, 280 (45), pp.38035-38046. 10.1074/jbc.M502938200. pasteur-03237002

HAL Id: pasteur-03237002

https://pasteur.hal.science/pasteur-03237002

Submitted on 26 May 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# FLI-1 Functionally Interacts with PIASxα, a Member of the PIAS E3 SUMO Ligase Family*

Received for publication, March 17, 2005, and in revised form, August 23, 2005 Published, JBC Papers in Press, September 7, 2005, DOI 10.1074/jbc.M502938200

Emile van den Akker†<fnref n="1" />, Sabine Ano†<fnref n="1" />,<fnref n="2" />, Hsiu-Ming Shih§, Ling-Chi Wang§, Martine Pironin‡, Jorma J. Palvimo¶, Noora Kotaja||, Olivier Kirsh**, Anne Dejean**, and Jacques Ghysdael‡<fnref n="3" />

From the ‡Institut Curie, CNRS UMR 146, 91405 Orsay, France, the §Institute of Biomedical Sciences, Academia Sinica, 11529 Taipei, Taiwan, the ||Department of Medical Biochemistry, University of Kuopio, FIN 70211 Kuopio, Finland, the ¶Institute of Biomedicine, Biomedicum Helsinki, University of Helsinki, FIN 00014 Helsinki, Finland, and the **Institut Pasteur, INSERM U579, 75015 Paris, France

FLI-1 is a transcription factor of the ETS family that is involved in
several developmental processes and that becomes oncogenic when
overexpressed or mutated. As the functional regulators of FLI-1 are
largely unknown, we performed a yeast two-hybrid screen with
FLI-1 and identified the SUMO E3 ligase PIASxα/ARIP3 as a novel
*in vitro* and **in vivo** binding partner of FLI-1. This interaction
involved the ETS domain of FLI-1 and required the integrity of the
SAP domain of PIASxα/ARIP3. SUMO-1 and Ubc9, the ubiquitin
carrier protein component in the sumoylation pathway, were also
identified as interactors of FLI-1. Both PIASxα/ARIP3 and the
closely related PIASxβ isoform specifically enhanced sumoylation
of FLI-1 at Lys⁶⁷, located in its N-terminal activation domain.
PIASxα/ARIP3 relocalized the normally nuclear but diffusely dis-
tributed FLI-1 protein to PIASxα nuclear bodies and repressed
FLI-1 transcriptional activation as assessed using different ETS-
binding site-dependent promoters and different cell systems.
PIASxα repressive activity was independent of sumoylation and did
not result from inhibition of FLI-1 DNA-binding activity. Analysis
of the properties of a series of ARIP3 mutants showed that the
repressive properties of PIASxα/ARIP3 require its physical interac-
tion with FLI-1, identifying PIASxα as a novel corepressor of FLI-1.

FLI-1 (Friend leukemia integration-i) is an ETS (E26 transformation-
specific) transcription factor that plays an essential role in the
megakaryocytic, granulocytic, and erythrocytic lineages and in endothe-
lial cell development (1-4). FLI-1 shares, with other ETS family mem-
bers, a conserved ETS domain responsible for nuclear targeting and
specific binding to DNA elements containing a consensus GGA(A/T)
core (ETS-binding site (EBS))<fnref n="4" /> (for review, see Ref. 5). FLI-1 also pos-
sesses a pointed/SAM domain embedded in its major N-terminal acti-
vation domain and a C-terminal domain that also contributes to its

transcriptional activation properties (for review, see Ref. 5). Consistent
with its biochemical and biological functions, a number of genes specific
to the megakaryocytic, granulocytic, and erythrocytic lineages have
been found to be down-regulated in FLI-1-deficient bone marrow cells,
with a subset of these genes being direct transcriptional targets of FLI-1
(Refs. 1, 3, and 4, and references therein). Remarkably, lineage-restricted
expression of many megakaryocyte-specific genes relies on the cooper-
ation between FLI-1 and GATA-1 on composite DNA elements present
in their promoter/enhancer sequences (Ref. 6 and references therein).
Depending on the cell and promoter contexts, FLI-1 can also repress
EBS-driven transcription through ill characterized mechanisms (7, 8).
Finally, FLI-1 can interact in *trans* with other transcriptional regulators,
including nuclear hormone receptors and erythroid-specific Krüppel-
like factor, thereby modifying transcriptional output in pathways
involving these factors (9, 10).

FLI-1 was originally identified as a common proviral integration site in
erythroleukemia induced in newborn mice by the Friend murine leuke-
mia virus component of the Friend virus complex (for review, see Ref. 5).
Consistent with its central role in Friend murine leukemia virus-in-
duced erythroleukemia, enforced expression of FLI-1 in primary eryth-
roblasts and erythroleukemic cell lines has been shown to strongly
interfere with the normal, erythropoietin-induced differentiation of
these cells (8, 11), an activity that requires its EBS-dependent transcrip-
tional activation properties (12, 13). Other studies show that FLI-1
might also contribute to the transformed phenotype through interfer-
ence with the expression of genes important to erythroblast differenti-
ation (8, 10, 14). FLI-1 is rearranged in Ewing sarcoma (a childhood
pediatric tumor of neuroectodermal origin) as a result of a t(11;22)(q24;
q12) chromosomal translocation that fuses the 5'-end of the *EWS* gene
to the 3'-end of *FLI-1* and the expression of a chimeric *EWS-FLI-1*
protein endowed with abnormal transcriptional regulatory properties
and transforming activity (for review, see Ref. 15).

PIAS1 (protein inhibitor of activated STAT proteins) and PIAS3 have been identified as inhibitors of the cytokine receptor/JAK (Janus kinase)-induced activation of STAT1- and STAT3-DNA binding, respectively. In mammals, the PIAS family also includes PIASxα, PIASxβ, and PIASy. PIAS proteins share three conserved domains: an N-terminal SAP (SAF/Acinus/PIAS) domain, a central RING finger-like domain, and a C-terminal serine/acidic residue-rich domain. The SAP domain binds AT-rich DNA sequences known as the scaffold or nuclear matrix attachment region, involved in the topological organization of chromatin and in the regulation of gene expression (for review, see Ref. 16). The RING finger-like domain of PIAS proteins is instrumental in their ability to function as SUMO E3 ligases that favor the covalent modification of a variety of target proteins by the three known members of the SUMO (small ubiquitin-like modifier) family (for review, see Ref.

<footnote>* This work was supported in part by CNRS, the Institut Curie, the Ligue Nationale contre le Cancer (Equipe Labellisée La Ligue 2004), and the Association for International Cancer Research (to J. G.) and by the Academy of Finland (to J. J. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "*advertisement*" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</footnote>

<footnote n="1">¹ Both authors contributed equally to this work.</footnote>

<footnote n="2">² Supported by a predoctoral fellowship from the Ministère de l'Éducation Nationale et de la Recherche and the Association pour la Recherche contre le Cancer.</footnote>

<footnote n="3">³ To whom correspondence should be addressed: Institut Curie, Centre Universitaire, CNRS UMR 146, Bat. 110, 91405 Orsay, France. Tel.: 33-1-6986-3152; Fax: 33-1-6907-4525; E-mail: Jacques.Ghysdael@curie.u-psud.fr.</footnote>

<footnote n="4">⁴ The abbreviations used are: EBS, ETS-binding site; STAT, signal transducer and activator of transcription; E3, ubiquitin-protein isopeptide ligase; E1, ubiquitin-activating enzyme; E2, ubiquitin carrier protein; ERK2, extracellular signal-regulated kinase-2; HA, hemagglutinin; Gal4AD, Gal4 activation domain; GST, glutathione S-transferase; wt, wild-type; Luc, luciferase; m, mouse; PBS, phosphate-buffered saline.</footnote>
FLI-1 Functionally Interacts with PIASxα

17). Sumoylation is a three-step process similar to protein ubiquitinyla-
tion, involving a SUMO-activating enzyme (E1; AOS1/UBA2); a SUMO
carrier protein (E2; Ubc9); and E3 ligases, including Ran-binding pro-
tein-2, Polycomb-2, and PIAS proteins. Sumoylation regulates a num-
ber of protein-protein interactions involved in critical cellular func-
tions, including protein stability, nuclear import, transcriptional
regulation, biogenesis of subnuclear bodies, and chromosome structure.

As the functional regulators of FLI-1 are largely unknown, we per-
formed a yeast two-hybrid screen to identify novel FLI-1 interactors.
We identified PIASxα/ARIP3 as a new partner and co-regulator of
FLI-1. ARIP3 was found to interact physically with FLI-1, to repress its
transcriptional activity, and to sequester it into PIASxα/ARIP3 nuclear
bodies. FLI-1 is sumoylated at a single lysine residue in its transcrip-
tional activation domain, and ARIP3 is shown to be a SUMO E3 ligase
for FLI-1 *in vivo* and *in vitro*. Interestingly, the repressive properties of
ARIP3 are not dependent upon its SUMO ligase activity and FLI-1
sumoylation, but critically depend upon its ability to physically complex
FLI-1 into a transcriptionally inactive protein complex.

EXPERIMENTAL PROCEDURES

*Reagents*—Anti-FLI-1 (catalog no. sc-356) and anti-ERK2 (catalog no. sc-154) antibodies were purchased from Santa Cruz Biotechnology, Inc. Anti-FLAG antibody (catalog no. F-3164) was purchased from Sigma, and anti-hemagglutinin (HA; catalog no. 1667475) was from Roche Applied Science. The anti-pan ETS antibody was a kind gift from Dr. N. Bhat. Anti-ARIP3 antibody has been described previously (18).

*Yeast Two-hybrid Screen*—The DNA fragment encoding FLI-1-(225–373) was subcloned in-frame with the LexA DNA-binding domain in the BTM116 vector to produce the bait for yeast two-hybrid studies. A human bone marrow cDNA library fused to the Gal4 activation domain (Gal4AD) was from Clontech. Yeast two-hybrid screening was performed as described previously (19), and a total of 5 × 10⁶ transformants were screened. Positive clones were selected on plates lacking uracil, histidine, tryptophan, lysine, and leucine, followed by β-galactosidase assays, and verified by one-on-one transformation assays.

*DNA Constructs*—To obtain the glutathione S-transferase (GST)-FLI-1-(3–208), GST-FLI-1-(3–286), GST-FLI-1-(188–452), and GST-FLI-1-(250–452) fusion proteins, the corresponding regions were PCR-amplified from the human *FLI-1* cDNA using pBS-wtFLI-1 (13) as a matrix with 5'-CCG TCG ACG GGA CTA TTA AGG AGG CTC TGT CG-3' as the forward primer and 5'-GGG TCG ACG GTG TGG GAG GTT GTA TTA TAG G-3' and 5'-GGG TCG ACA GGA ATT GCC ACA GCT GGA TCT GC-3' as the reverse primers for FLI-1-(3–208) and FLI-1-(3–286), respectively, and 5'-CCG GAT CCT TGT CAC ACC TCA GTT ACC TCA GG-3' and 5'-CCG GAT CCA TCA GTA AGA ATA CAG AGC AAC G G-3' as the forward primers for FLI-1-(188–452) and FLI-1-(250–452), respectively, and 5'-GGG TCG ACA AGC TTC TAG TAG CTG CC-3' as the reverse primer. This resulted in flanking the PCR-amplified fragment either with a Sall restriction site for FLI-1-(3–208) and FLI-1-(3–286) or with BamHI and Sall for the fragments encoding FLI-1-(188–452) and FLI-1-(250–452) at their 5'- and 3'-ends, respectively. The respective Sall- or BamHI/ Sall-digested PCR fragments were inserted in Sall- or BamHI/Sall-cut pGEX-4T. To generate pBS-HA-wtFLI-1, ΔEB-HA-FLI-1 (20) was partially digested with SstI and EcoRI and ligated into SstI/EcoRI-restricted pBluescript. Mutants FLI-1(K67R) and FLI-1(K217R) were generated by oligonucleotide site-directed mutagenesis with the QuikChange kit (Stratagene) following the manufacturer's instructions using pBS-HA-wtFLI-1 as a matrix and mutagenic primers 5'-GGG TCA ACG TCA

GGC GGG AGT ATG ACC-3'/5'-GGT CAT ACT CCC GCC TGA
CGT TGA CCC-3' and 5'-CCT CAC GAT TGA GTG TCA GAG AAG
ACC CTT CTT ATG AC-3'/5'-GTC ATA AGA AGG GTC TTC TCT
GAC ACT CAA TCG TGA GG-3', respectively. The double point
mutant FLI-1(K67R,K217R) was generated using pBS-HA-FLI-1(K67R)
as a matrix and the mutagenic primers used for FLI-1(K217R). To gen-
erate HA-tagged versions of these mutants in the corresponding ΔEB
expression vector derivatives, mutagenized FLI-1 inserts were retrieved
by XhoI/HindIII digestion and ligated into XhoI/HindIII-restricted
ΔEB-HA (21). The expression vectors pSG5-His-SUMO-1 and pSG5-
His-HA-SUMO-2 (22) and the pFLAG expression vectors encoding
wild-type (wt) ARIP3, ARIP3-(Δ13-28), ARIP3-(Δ1-102), ARIP3-
(Δ102-207), ARIP3-(Δ198-337), ARIP3-(Δ347-418), ARIP3-(Δ346-
475), ARIP3-(Δ467-547), ARIP3-(Δ467-487), and ARIP3(W383A) as
well as in vitro translatable pTag2A-wtARIP3, pTag2A-ARIP3-(Δ102-
207), pTag2A-ARIP3-(Δ347-418), and pTag2A-MIZ/PIASxβ have
been described previously (23, 24). To generate pTag2A-ARIP3-(Δ13-
28), pTag2A-ARIP3-(Δ198-337), and pTag2A-ARIP3-(Δ346-475),
the SmaI/BglII cDNA inserts from the respective pFLAG vectors were
subcloned into EcoRV/BamHI-restricted pTag2A (Stratagene). The
ΔEB expression plasmids encoding HA-wtFLI-1, HA-FLI-1-(276-373),
tkD2A-luciferase (Luc), and mouse (m) FLI-1-(-270/-41)-Luc have
been described previously (12, 13). FLI-1-(273-452) was made as fol-
lows. Using ΔEB-HA-wtFLI-1 as a template, the FLI-1 DNA fragment
corresponding to amino acids 273-452 was amplified using oligonu-
cleotides 5'-GCC TCG AGG CCT GGA AGC GGG CAG ATC C-3'
containing a 5'-XhoI site) and 5'-CCA AGC TTC TAG TAG CTG CC-3'
containing a 3'-HindIII site). The amplified DNA frag-
ment was digested with XhoI and HindIII and ligated in-frame into
XhoI/HindIII-digested ΔEB-HA to generate ΔEB-HA-FLI-1-(273-
452). pSG513-3'HA-BirA was a kind gift from Dr. T. B. van Dijk (Eras-
mus Medical Center). pcDNA3-biopeptide-FLI-1(M34A) was gener-
ated as follows. An oligonucleotide encoding the biopeptide
(MASSMRQILDSQKMEWRSNAGGS), 5'-CCG ATA TCC CAC
CAT GGC CTC TTC CCT GAG ACA GAT CCT CGA CAG CCA
GAA GAT GGA GTG GCG CTC CAA CGC AGG AGG CTC TAG
ATC TCC C-3', was used as a PCR template with 5'-CCC GAT ATC
CCA CCA TGG-3' (containing a 5'-EcoRV site) and 5'-GGG AGA
TCT AGA GCC TCC-3' (containing a 3'-BglII site) as primers, and the
PCR product was ligated into pCR2.1-TOPO, generating pCR2.1-
TOPO-biopeptide. pCR2.1-TOPO-biopeptide was digested with
EcoRV and BglII, and the fragment was ligated into EcoRV/BglII-di-
gested pBS-HA-FLI-1, replacing, in-frame, the HA tag with the biopep-
tide tag. wtFLI-1 contains an alternative translation initiation codon at
position 34. To prevent alternative translation from AUG at position 34,
this codon was mutated into an alanine codon using a site-directed
mutagenesis kit and primers 5'-GGA CTC CCC GAG GCA GTC GCG
TCG GCC TTG GGG AGA TGG-3' and 5'-CCA TCA CCC CAA
GGC CGA CGC GAC TGC CTC GGG GAG TCC-3'. Biopeptide-FLI-
1(M34A) was released from the pBS vector by digestion with HindIII
and ligated into HindIII-digested pcDNA3 to generate pcDNA3-
biopeptide-tagged FLI-1(M34A), referred to as biotagged FLI-1 under
"Results." HA-ARIP3 was made as follows. Using FLAG-ARIP3 as a
template, wtarip3 cDNA was amplified and fused N-terminally to an
HA epitope by PCR with primers 5'-GGA GAT CTG CAA CCA TGT
ACC CAT ACG ATG TTC CAG ATT ACG CGG CGG ATT TCG
AGG AGT TGA GG-3' (containing a 5'-BglII site, followed by the
cDNA encoding the HA epitope fused in-frame to the first 20 nucleo-
tides of wtARIP3) and 5'-CGG AAT TCT CAC TGT TGC ACA GTA
TCA GA-3' (containing a 3'-EcoRI site). The PCR product was cut with
FLI-1 Functionally Interacts with PIASα

BglII and EcoRI and ligated into BamHI/EcoRI-digested pcDNA3, yielding pcDNA3-HA-wtARIP3.

*Affinity Chromatography of Biotinylated Proteins and Immunoprecipitation and Western Blot Analyses*—293 cells (1.0 × 10⁶) were seeded in 60-mm² Petri dishes 24 h prior to transfection, and DNA was transfected using the calcium phosphate coprecipitation method as described previously (25). 48 h after transfection, cells were washed twice with ice-cold phosphate-buffered saline (PBS), lysed in ice-cold lysis buffer (20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 10 mM EDTA, 50 nM NaF, 1% (v/v) Nonidet P-40, 10% (v/v) glycerol, 2 mM Na₃VO₄, 1 mM Pefabloc (Roche Applied Science), 50 mg/ml aprotinin, 50 mg/ml leupeptin, 50 mg/ml bacitracin, and 50 mg/ml iodoacetamide) on ice for 10 min, frozen in liquid nitrogen, and stored at −80 °C until used. Lysates were thawed on ice and cleared by centrifugation at 15,000 rpm for 10 min at 4 °C. For immunoprecipitations, lysates were incubated for 1 h with 1 µg of a specific IgG as indicated in the legends, followed by a 1-h incubation with 15 µl of 50% protein A-agarose bead slurry (Amersham Biosciences). The beads were washed three times with ice-cold lysis buffer, followed by one washing step with ice-cold PBS and boiling in SDS-PAGE sample buffer for 5 min. For affinity chromatography of biotinylated FLI-1, lysates were incubated for 1 h with 10 µl of magnetic polystyrene beads covalently coupled to streptavidin (Dynabeads M-280; 50% slurry washed three times and reconstituted in ice-cold lysis buffer). Magnetic beads were washed three times as described above for immunoprecipitation assays, except that a magnet (catalog no. Z5342, Promega Corp.) was used for fast recovery of the beads. SDS-PAGE and Western blotting were performed as described previously (26). Membranes were stripped in 63 mM Tris-HCl (pH 6.1), 2% SDS, and 100 mM β-mercaptoethanol for 30 min at 50 °C, after which they were reused. When appropriate, fluorescence was detected using GeneSnap Version 6.01 (SYNGENE, Cambridge, UH) and quantified with GeneTools software (SYNGENE). Images were processed using Adobe Photoshop Version 6.0.

*Luciferase Assays and Immunofluorescence Analyses*—For transactivation experiments, 3 × 10⁵ HeLa or 293 cells grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Invitrogen) were plated in six-well plates and transfected 24 h later with the indicated amount of plasmid DNA by calcium phosphate coprecipitation of DNA as described above. The total amount of expression plasmid was kept constant by addition of the corresponding empty vector without insert, and the total amount of DNA (20 µg/500 µl) was kept constant by addition of carrier plasmid DNA. Cell lysates were prepared 24 h after transfection and assayed for luciferase activity using the luciferase assay system kit (Promega). The results shown are the mean of at least three independent transfection experiments.

For immunofluorescence analyses, 1.5 × 10⁵ 293 cells were seeded per well in 12-well plates containing 14-mm² glass coverslips (Marienfeld MultiMedia GmbH, Essen, Germany). After 24 h, cells were transfected with 1 µg of ΔEB-HA-FLI-1 and 1.5 µg of pFLAG-ARIP3 and mutants derived thereof as indicated using the calcium phosphate coprecipitation method. The total amount of expression plasmid was kept constant by addition of the corresponding empty vector without insert, and the total amount of DNA (20 µg/500 µl) was kept constant by addition of carrier plasmid DNA. 2 days after transfection, the cells were washed two times with PBS, fixed with 4% paraformaldehyde in PBS (15 min), and permeabilized by incubation in 0.3% Triton X-100 (15 min). After washing with PBS, the cells were incubated for 1 h with a 1:200 dilution of anti-FLI-1 antibody and a 1:100 dilution of anti-FLAG antibody in PBS containing 10% fetal calf serum at 37 °C. Cells were washed three times with PBS and incubated for 1 h at 37 °C with fluo-

reschein isothiocyanate-conjugated goat anti-rabbit immunoglobulin (1:100 dilution), Texas Red-coupled donkey anti-mouse antibody (1:100 dilution), and 50 µg/ml Hoechst dye (all obtained from Jackson ImmunoResearch Laboratories, Inc.) diluted in PBS containing 10% fetal calf serum. Coverslips were washed two times with PBS and mounted in Dabco. Pictures of fixed cells were collected using a three-dimensional deconvolution imaging system. In brief, a Leica DM RXA microscope equipped with a piezoelectric translator (PIFOC, Physik Instrumente L. P.) placed at the base of a ×100 PlanApo numerical aperture 1.4 objective and a 5-MHz Micromax 1300Y interline CCD camera (Roper Instruments) was used. Stacks of conventional fluorescent images were collected automatically at 0.2-µm z-intervals (MetaMorph software, Universal Imaging Corp.). Wavelength selection was achieved by switching to the corresponding motorized selective Leica filter block before each stack acquisition. Automated batch deconvolution of each z-series was computed using a measured point spread function with a custom-made software package (J. B. Sibarita, Institut Curie).

*DNA Binding by Electrophoretic Mobility Shift Assays and Oligonucleotide Pull-down Assay*—Electrophoretic mobility shift assays were performed essentially as described previously (20). For the oligonucleotide pull-down assay, a double-stranded DNA oligonucleotide corresponding to a high affinity FLI-1-binding site (wild-type, 5'-TCG GGT CGA CAT AAC CGG AAG TGG GC-3' ((+)-strand), with the EBS core sequence underlined) was synthesized as a 5'-biotinylated derivative. A version of this oligonucleotide mutated in the EBS core (5'-TCG GGT CGA CAT AAC CCC AAG TGG GC-3' ((+)-strand), with the mutations shown in boldface) was used a negative control. The oligonucleotides were immobilized on streptavidin beads by overnight incubation at 4 °C in binding buffer (10 mM Tris-HCl (pH 8.0), 10% glycerol, 6 mM MgCl₂, 5 mM dithiothreitol, 0.1 mM EDTA, 0.01% Nonidet P-40, and 10 µg/µl poly(dI·dC)) supplemented with 1% bovine serum albumin at a final ratio of 0.6 µg of oligonucleotide/1 × 10⁶ beads. After three washes, the EBS oligonucleotide-streptavidin beads were equilibrated in binding buffer. The efficiency of oligonucleotide loading onto the streptavidin beads was checked in a small aliquot by detaching the EBS from the beads by incubation at 90 °C in 0.1% SDS and resolving the extract on a 1.5% agarose gel in the presence of ethidium bromide. Whole cell extracts were obtained (100-mm² Petri dish in 300 µl of lysis buffer) from 293 cells transfected with the expression vector for HA-FLI-1 (1 µg) with or without the expression vector for HA-ARIP3 (1 µg) or empty vector as a control. Lysates (100 µl) were diluted with 2 volumes of binding buffer, keeping poly(dI·dC) constant at 10 µg/µl, and incubated with 7 × 10⁶ oligonucleotide-immobilized beads for 60 min at 4 °C. The DNA affinity matrix was washed three times with binding buffer, and bound proteins were eluted by boiling in SDS-PAGE sample buffer. Boiled extracts were subjected to SDS-PAGE and Western blotting.

*In Vitro and in Vivo SUMO Conjugation*—*In vitro* sumoylation assays performed with 2 µl of *in vitro* translated wtFLI-1 protein in reticulocyte lysate (Promega) were performed as described previously (27). To detect sumoylated FLI-1 *in vivo*, 0.5 × 10⁶ HeLa cells were seeded in 60-mm² Petri dishes and transfected 24 h later with ΔEB-HA-FLI-1 along with pSG5-His-SUMO-1 or pSG5-His-HA-SUMO-2 as indicated. After 48 h, cells were washed twice with ice-cold PBS and lysed in 1 ml of 6 M guanidinium chloride, 0.1 M NaH₂PO₄, and 10 mM Tris-HCl (pH 8.0), and 50 µl of lysate was precipitated with 1 ml of 5% trichloroacetic acid for 2 h at room temperature. After centrifugation at 15,000 rpm for 30 min, the trichloroacetic acid protein precipitates were rinsed two times with acetone, air-dried, resuspended in 20 µl of SDS-PAGE sample buffer, and subjected to SDS-PAGE and Western blotting. To
FLI-1 Functionally Interacts with PIASxα

<figure><img src="image_2.png" /><figcaption>FIGURE 1. Schematic diagram of the FLI-1 protein and the interaction of FLI-1 and PIASxα. A, shown is a diagram of the FLI-1 functional domains. The ETS domain is shown as a hatched box, and the pointed/SAM domain as a gray box. NTAD, N-terminal activation domain; CTAD, C-terminal activation domain. The LexA fusion protein encompassing amino acids 225–373 of FLI-1, used as bait in the yeast two-hybrid screen, is depicted. LexA-MST3 (full-length) was used as a negative control. B, transformants were assayed for β-galactosidase activity and analyzed by LacZ staining. C, 293 cells were transfected with combinations of expression plasmids encoding the indicated proteins. Biotagged FLI-1 (Bio-FLI-1) was isolated by affinity chromatography using streptavidin beads (upper panels) or by immunoprecipitation (IP) using anti-FLI-1 antibody (middle panels) as described under “Experimental Procedures,” and blots were processed for Western analyses using anti-FLAG, anti-ARIP3, or anti-FLI-1 antibody to detect FLAG-ARIP3 and FLI-1. Whole cell lysates (WCL) used in the immunoprecipitation and affinity chromatography analyses were subjected to SDS-PAGE and processed for Western blotting using anti-ARIP3, anti-FLI-1, or anti-HA antibody to confirm expression and input of the respective proteins (lower panels).</figcaption></figure>

detect ARIP3-mediated FLI-1 sumoylation in vivo, 0.5 × 10⁶ 293 cells were seeded in 60-mm² Petri dishes and transfected with ΔEB-HA-wtFLI-1 together with pSG5-His-SUMO-1 and/or pFLAG-wtARIP3 when appropriate. After 48 h, the cells were washed twice with ice-cold PBS and lysed directly in 200 µl of SDS-PAGE sample buffer. Lysates were sonicated for 20 s on ice at low intensity to fragment genomic DNA, and 20 µl was subjected to SDS-PAGE and Western blotting.

RESULTS

Isolation of the SUMO Ligase PIASxα as a Binding Partner of FLI-1 in
a Yeast Two-hybrid Screen—In a search for potential partners of FLI-1,
a yeast two-hybrid screen of a human bone marrow cDNA library was
performed using, as bait, a fusion between the LexA DNA-binding
domain and amino acids 225–373 of FLI-1 (LexA-FLI-1-(225–373)).
This region includes a domain unique to the FLI-1/ERG subfamily of
ETS proteins (residues 257–276) as well as the entire ETS domain (Fig.
1A). Three interactors involved in the post-translational modification of
proteins by SUMO, including SUMO-1 itself, Ubc9, and PIASxα, were
identified as positive clones in this screen. These interactions were spe-
cific because coexpression of LexA-FLI-1-(225-373) with Gal4AD-
PIASxα, Gal4AD-SUMO-1, or Gal4AD-Ubc9 activated the lacZ
reporter present in the indicator yeast strain, whereas the control LexA-
MST3 bait failed to interact with any of these Gal4AD fusion proteins
(Fig. 1B). Of note, LexA-FLI-1-(225-373) did not auto-activate the lacZ
reporter (data not shown).

To analyze whether FLI-1 and PIASxα interact in vivo, 293 cells were cotransfected with expression vectors encoding a FLAG-tagged version of rat PIASxα (also known as ARIP3) (18), FLI-1, and the *Escherichia coli* BirA biotin ligase. The FLI-1 protein used in this study was tagged at its

N-terminal end with a 23-amino acid peptide selected as a highly spe-
cific biotinylation substrate for E. coli BirA through iterative screening
of combinatorial libraries (Ref. 28 and references therein). Under these
conditions, biotagged FLI-1 was efficiently biotinylated by BirA (data
not shown), allowing its rapid and essentially quantitative purification
from cell extracts by affinity chromatography on a streptavidin affinity
matrix. As shown in Fig. 1C, coexpression of biotagged FLI-1, ARIP3,
and BirA resulted in the co-purification of ARIP3 and affinity-purified
FLI-1 as detected by Western blot analyses using antibody to either
FLAG or ARIP3 (Fig. 1C, *upper panels, lane 3*). No such co-purification
was detected when the BirA expression plasmid was omitted from the
cotransfection mixture (Fig. 1C, *upper panels, lane 5*). The interaction
between FLI-1 and ARIP3 was also observed using anti-FLI-1 antibody
in a conventional co-immunoprecipitation assay (Fig. 1C, *middle
panels*).

ARIP3 Interacts in Vivo with FLI-1 in a SAP Domain-dependent Fashion—To identify the domains of ARIP3 that are involved in its ability to associate with FLI-1, we compared the ability of a series of ARIP3 deletion mutants (Fig. 2A) and wtARIP3 to interact with FLI-1. As shown in Fig. 2B, ARIP3-(Δ102–207), ARIP3-(Δ198–337), and SUMO ligase-deficient ARIP3-(Δ347–418) and ARIP3-(Δ346–475) co-purified with FLI-1. This shows that most of the N-terminal domain and the zinc finger domain of ARIP3 are not essential for this interaction. In sharp contrast, disruption of the ARIP3 SAP domain by deletion of amino acids 13–28 (ARIP3-(Δ13–28) abolished the ability of ARIP3 to interact with FLI-1 as analyzed by either affinity purification or co-immunoprecipitation (Figs. 1C and 2B).

The C-terminal part of FLI-1 (amino acids 225–373) was sufficient for its interaction with ARIP3 in the yeast two-hybrid experiments. This
FLI-1 Functionally Interacts with PIASxα

<figure><img src="image_3.png" /></figure>

**FIGURE 2.** The interaction between FLI-1 and ARIP3 depends on the ETS domain of FLI-1 and the integrity of the SAP domain of ARIP3. A, shown is a schematic representation of the different N-terminally FLAG-tagged ARIP3 deletion mutants used in this study. B, 293 cells were transfected with expression vectors encoding the indicated proteins. FLI-1 was isolated by affinity chromatography using streptavidin beads; the isolated proteins were subjected to SDS-PAGE; and the gels were processed for Western blotting (upper panels). Blots were stained with anti-FLAG (to detect FLAG-tagged ARIP3) and anti-FLI-1 antibodies. The whole cell lysate (WCL) used for the affinity chromatography purification was analyzed to confirm expression of the different ARIP3 mutants (anti-FLAG antibody) and of BirA (anti-HA antibody) (lower panels). The asterisks indicate wtARIP3 and mutants derived thereof. *Bio-FLI-1*, biotagged FLI-1. C, 293 cells were transfected with expression vectors encoding the indicated proteins. FLI-1 mutants were immunoprecipitated (IP) using anti-pan ETS antibody (which recognizes the ETS domain), and the immunoprecipitates were subjected to SDS-PAGE and Western blotting. Blots were analyzed for the presence of ARIP3 in the FLI-1 precipitates using anti-ARIP3 antibody (upper panel). The whole cell lysate used for the immunoprecipitation was analyzed by Western blotting to confirm the expression of ARIP3 using anti-ARIP3 antibody (lower panel). D, 293 cells were transfected with expression vectors encoding the indicated proteins. ARIP3 was immunoprecipitated using anti-ARIP3 antibody, and immunoprecipitates (upper panels) as well as whole cell lysates (lower panels) were subjected to SDS-PAGE and Western blotting. Blots were stained with the indicated antibodies.

region of FLI-1 includes the entire ETS domain (amino acids 277–361) and an upstream region conserved in the FLI-1/ERG subfamily of ETS proteins. Besides its specific interaction with DNA, the ETS domain mediates interactions with a number of proteins, including GATA-1 (6) and erythroid-specific Krüppel-like factor (10). We next analyzed whether this region of FLI-1 is involved in the interaction with ARIP3 *in vivo*. As is apparent in Fig. 2C, wtFLI-1 and its isolated ETS domain (FLI-1-(276–373)) were equally efficient in co-immunoprecipitating ARIP3, showing that the ETS domain is sufficient to mediate the interaction with ARIP3. This interaction was specific, as the antibody directed against the ETS domain of FLI-1 did not coprecipitate ARIP3 when the wtFLI-1 or FLI-1-(276–373) expression vector was omitted from the transfection mixture (Fig. 2C, lane 4). Similar to wtFLI-1, the interaction of the ETS domain (FLI-1-(276–373)) with ARIP3 depended upon the integrity of the SAP domain, as the ETS domain failed to coprecipitate with ARIP3-(Δ13–28) (Fig. 2D). We conclude from these experiments that FLI-1 specifically interacts with ARIP3 *in vivo* and that this interaction involves the ETS domain of FLI-1 and requires the integrity the SAP domain of ARIP3.

*The Interaction between FLI-1 and ARIP3 Is Direct and Does Not Require Cofactors*—To analyze whether the interaction between FLI-1 and ARIP3 is direct, we next performed GST pull-down experiments using, as affinity matrices, a series of GST fusion proteins corresponding

to specific functional domains of FLI-1 (Fig. 3A). Full-length wtARIP3 and a series of ARIP3 deletion mutants were synthesized as radiolabeled proteins by *in vitro* translation, and their association with the different GST-FLI-1 fusion proteins and control GST was compared. As shown in Fig. 3B, GST-FLI-1-(3–208) and GST-FLI-1-(3–286), which encompass the N-terminal half of FLI-1, including its pointed/SAM domain, failed to pull down ARIP3. In contrast, both GST-FLI-1-(188–452) and GST-FLI-1-(250–452), which span the C-terminal part of FLI-1, including its ETS domain, specifically bound ARIP3. In line with the results obtained *in vivo*, disruption of the SAP domain in ARIP3-(Δ13–28) inhibited the ability of ARIP3 to interact with GST-FLI-1-(250–452) (Fig. 3C). In contrast, deletion of amino acids 102–207 and 198–337 in the N-terminal half of the protein and the zinc finger domain (ARIP3-(347–418)) and downstream sequences (ARIP3-(346–475)) did not affect ARIP3 binding to FLI-1. PIASx is expressed in two isoforms, PIASxα and PIASxβ, which differ only at their extreme C-terminal ends. As expected from the results obtained with PIASxα/ARIP3, PIASxβ was coprecipitated as efficiently as ARIP3 by GST-FLI-1-(250–452) (Fig. 3C).

*ARIP3 and PIASxβ Stimulate FLI-1 Sumoylation in Vitro*—Ubc9 and PIASxα/ARIP3 are critical components of the SUMO modification pathway of proteins, in which Ubc9 is the E2 conjugating enzyme, whereas PIASxα/ARIP3 and other PIAS family members are E3 ligases
FLI-1 Functionally Interacts with PIASxα

<figure><img src="image_4.png" /><figcaption>FIGURE 3. **ARIP3 and FLI-1 interact directly in vitro.** A, shown is a schematic representation of the different FLI-1 deletion mutants fused to GST used in this study. The ETS domain is shown as a *hatched box*; the pointed/SAM domain is shown as a *gray box*; and the GST domain is shown as a *gray oval*. **NTAD**, N-terminal transcriptional activation domain; **CTAD**, C-terminal transcriptional activation domain. **B** and **C**, GST-FLI-1 deletion mutants were isolated from transformed and isopropyl β-D-thiogalactopyranoside-induced bacteria, purified on glutathione-agarose beads, and incubated with *in vitro* transcribed/translated [³⁵S]methionine/cysteine-labeled wtARIP3 (B) or the indicated deletion mutants of ARIP3 (C). GST pull-down assays were performed as described under "Experimental Procedures," and bound proteins were subjected to SDS-PAGE, followed by fluorography of the dried gel.</figcaption></figure>

that facilitate SUMO conjugation to specific substrates (17). Because FLI-1 interacts physically with both Ubc9 and ARIP3, we next examined whether FLI-1 can be sumoylated *in vitro* and whether its sumoylation can be enhanced by PIAS proteins. L-[³⁵S]Methionine/cysteine-labeled HA-tagged wtFLI-1 produced by *in vitro* translation was incubated in the presence of ATP and a cellular fraction containing SUMO E1-activating activity together with recombinant Ubc9 and SUMO-1 in the absence or presence of recombinant PIAS proteins. As expected, translation of the *FLI-1* mRNA occurred both at the initiator methionine and at a second translation initiation AUG codon at position 34 (Fig. 4A, *lane 1*). In the presence of SUMO-1, two slow migrating forms were additionally observed, corresponding to the expected increase in apparent molecular mass resulting from addition of a single SUMO-1 adduct to each of the FLI-1 variants. Addition of PIAS3 or PIASy had no detectable effect on FLI-1 sumoylation levels, whereas PIAS1 clearly enhanced FLI-1 sumoylation (Fig. 4A). In contrast, addition of either PIASxα or PIASxβ strongly enhanced FLI-1 sumoylation and resulted in the

appearance of FLI-1 forms that most likely correspond to the conjugation of several SUMO adducts (Fig. 4A, *lanes 5* and 6). These results show that FLI-1 can be conjugated to SUMO-1 *in vitro* and that this modification is significantly enhanced by specific members of the PIAS family of SUMO ligases.

**Lysine 67 Is the Major SUMO Modification Site in FLI-1 in Vivo—**
Next, we investigated whether FLI-1 is sumoylated *in vivo*. Expression vectors encoding HA-tagged wtFLI-1 and either His-tagged SUMO-1 or His-HA-tagged SUMO-2 were transiently transfected into HeLa cells, followed by lysis in a guanidinium chloride-containing buffer (see "Experimental Procedures"), and whole cell extracts were analyzed by Western blotting using anti-FLI-1 antibody. HA-tagged FLI-1 migrates as a major species of 50 kDa and a minor component resulting from internal initiation at Met³⁴. In the presence of exogenous SUMO-1 or SUMO-2, slow migrating forms of FLI-1 were observed with an increase in apparent molecular mass corresponding to monosumoylation (Fig. 4B, *lanes 3* and 4). Of note, a band migrating below the exogenous SUMO-1- and SUMO-2-FLI-1 adducts was present in *lanes 2–4* and likely represents FLI-1 sumoylation with endogenous SUMO. Protein sumoylation often targets lysine residues in a φKXE consensus sequence, where K corresponds to the lysine residue to which SUMO-1 is covalently bound, φ to a hydrophobic amino acid, and X to any amino acid. Perfect or near perfect matches to this motif are found in FLI-1 around Lys⁶⁷ and Lys²¹⁷, both localized in the N-terminal half of the protein. To investigate whether these residues are *in vivo* acceptor sites for SUMO-1 or SUMO-2, they were mutated either singly or in combination to non-sumoyatable arginine to generate FLI-1-(K67R), FLI-1(K217R), and FLI-1-(K67R,K217R), respectively. Sumoylation of these mutants was compared with that of wtFLI-1 following transient transfection of the corresponding expression plasmids together with the expression plasmid for either SUMO-1 or SUMO-2. As shown in Fig. 4C, FLI-1(K217R) was modified as efficiently as wtFLI-1. In contrast, mutation of Lys⁶⁷ in FLI-1(K67R) and FLI-1(K67R,K217R) abolished the formation of the retarded sumoylated form of FLI-1. These results show that FLI-1 is sumoylated *in vivo* at a single lysine residue (Lys⁶⁷) located in its N-terminal domain and that both SUMO-1 and SUMO-2 can serve as substrates for this modification. Of note, the higher migrating forms of FLI-1 *in vitro*, presumably corresponding to multisumoylation of FLI-1, were not observed *in vivo*. Next, we studied whether ARIP3 is able to enhance sumoylation of FLI-1 *in vivo*. Fig. 4D shows that coexpression of FLI-1 with ARIP3 enhanced sumoylation of FLI-1 *in vivo*, using endogenous SUMO as a substrate (Fig. 4D, compare *lanes 1* and 4). Coexpression of HA-tagged SUMO-1 together with FLI-1 resulted in a second, slower migrating form of FLI-1 (corresponding to the covalent attachment of HA-tagged SUMO-1), which was enhanced by coexpression with ARIP3 (Fig. 4D, compare *lanes 2* and 4). These experiments indicate that FLI-1 is sumoylated at Lys⁶⁷ and that ARIP3 functions as a SUMO ligase for FLI-1 *in vitro* and *in vivo*.

**ARIP3 Interferes with FLI-1 Transcriptional Activity—**PIASxα/ARIP3 was originally characterized as an androgen receptor-interacting protein that functions as a co-regulator of the androgen receptor and other members of the nuclear hormone receptor family (18). PIASxα/ARIP3 was later shown to enhance sumoylation of cell proteins, and its SUMO ligase activity can be critical for PIASxα/ARIP3 to regulate transcription (24, 29). We therefore analyzed whether ARIP3 is able to modulate the transcriptional regulatory activity of FLI-1. Increasing amounts of the expression vector encoding ARIP3 were cotransfected together with fixed amounts of the FLI-1 expression plasmid and the EBS-driven luciferase reporter gene. Transactivation was monitored by luciferase activity assay. Consistent with previous results (13), FLI-1
FLI-1 Functionally Interacts with PIASxα

<figure><img src="image_5.png" /></figure>

FIGURE 4. FLI-1 is a SUMO substrate of specific PIAS family members *in vitro* and is sumoylated *in vivo*. A, recombinant proteins of different members of the PIAS family, HeLa cell extract containing SUMO E1-activating activity, and recombinant E2 (Ubc9) and SUMO-1 were incubated with *in vitro* transcribed/translated [³⁵S]methionine/cysteine-labeled wtFLI-1 for 1 h. Reaction contents were subjected to SDS-PAGE and fluorography of the dried gel to visualize the sumoylation pattern of FLI-1. FLI-1 migrates as a doublet due to a natural occurring alternative translation initiation site at AUG encoding Met³⁴. B and C, HeLa cells were transfected with combinations of expression vectors encoding the indicated proteins; cells were lysed; and whole cell lysates (WCL) were insolubilized with trichloroacetic acid, resuspended in SDS-PAGE sample buffer, subjected to SDS-PAGE, and processed for Western blotting using anti-FLI-1 antibody. D, 293 cells were transfected with combinations of expression vectors encoding the indicated proteins; cells were lysed as described under "Experimental Procedures"; and whole cell protein extracts were subjected to SDS-PAGE and Western blotting. The blot was successively stained with anti-FLI-1 (*upper panel*), anti-ARIP3 (*middle panel*), and anti-ERK2 (*loading control; lower panel*) antibodies. Arrows indicate the presence of wtFLI-1 and sumoylated FLI-1 adducts.

efficiently activated luciferase expression from tkD2A-Luc, a luciferase reporter gene in which a tandem copy of ETS-responsive region-1 of the human T-cell leukemia virus type I long terminal repeat is inserted upstream of the −55 herpes simplex virus thymidine kinase promoter (Fig. 5A). Increasing amounts of ARIP3 inhibited FLI-1-mediated transactivation of tkD2A-Luc in a dose-dependent manner (Fig. 5A). The inhibitory action of ARIP3 on FLI-1-mediated transactivation are not restricted to model promoters because ARIP3 also efficiently and specifically inhibited the EBS-dependent (30), FLI-1-mediated transactivation of the *mfli-1*-(−270/−41) gene promoter (Fig. 5A, *upper right panel*). Notably, ARIP3 did not affect the basal activity of either tkD2A-Luc or *mfli-1*-(−270/−41)-Luc, and it did not affect FLI-1 expression (Fig. 5A, *lower panels*).

Neither the Sumoylation of FLI-1 at Lys⁶⁷ nor the Ligase Activity of ARIP3 Is Essential for ARIP3 to Function as a Repressor of FLI-1 Transactivation—To determine whether ARIP3 repressive function depends upon FLI-1 sumoylation, we compared the ability of ARIP3 to inhibit wtFLI-1 and the sumoylation-defective FLI-1(K67R) mutant. As shown in Fig. 5B, transactivation of the *mfli-1*-(−270/−41)-Luc reporter gene by FLI-1(K67R) was similar to that induced by wtFLI-1 (Fig. 5B), indicating that the K67R mutation is without effect on FLI-1 transactivation properties. Of note, the DNA-binding ability of FLI-1(K67R) as assayed by electrophoretic mobility shift assay was similar to that of wtFLI-1 (data not shown). In addition, transactivation by wtFLI-1 or FLI-1(K67R) was similarly impaired in the presence of increasing amounts of ARIP3 (Fig. 5C), indicating that mutation of Lys⁶⁷ and therefore FLI-1 sumoylation are not required for ARIP3-mediated repression of FLI-1

transcriptional activity. Similar results were obtained using FLI-1(K67R,K217R) and tkD2A-Luc instead of *mfli-1*-(−270/−41)-Luc as the reporter gene construct (data not shown). We next examined whether the SUMO ligase activity of ARIP3 is required to inhibit FLI-1 transcriptional regulatory properties. To this end, we compared the inhibitory activity of wtARIP3 and either an ARIP3 mutant with a RING finger region deletion (ARIP3-(Δ347−418)) or a mutant in which a tryptophan residue conserved in the RING zinc finger of ARIP3 was changed to alanine (ARIP3(W383A)). Previous analyses have shown that both these mutations impair ARIP3 E3 activity (24). As shown in Fig. 5D, both ARIP3-(Δ347−418) and ARIP3(W383A) inhibited FLI-1-mediated transcriptional activation of *mfli-1*-(−270/−41)-Luc in a manner indistinguishable from wtARIP3. Taken together, these results show that the ARIP3 inhibitory action on FLI-1-induced transactivation requires neither the SUMO ligase activity of ARIP3 nor FLI-1 sumoylation. Notably, although PIASxβ was able to sumoylate and interact with FLI-1 *in vitro*, no repressive effect of PIASxβ on FLI-1 transactivation could be observed under these experimental conditions (data not shown).

ARIP3 Relocalizes FLI-1 to Nuclear Bodies—PIAS proteins localize to specific nuclear bodies of unclear composition and function that are detected as punctate structures by confocal immunofluorescence microscopy (23, 31, 32). To examine whether ARIP3 can change FLI-1 subnuclear localization, indirect two-color immunofluorescence was performed in cells expressing either wtFLI-1 or ARIP3 alone or together. As shown in Fig. 6A, single-plane microscopy revealed an essentially diffuse nuclear pattern for FLI-1 when expressed alone. In
<figure><img src="image_6.png" /><figcaption>FLI-1 Functionally Interacts with PIASα</figcaption></figure>

**FIGURE 5.** *ARIP3 represses FLI-1-induced transactivation.* A, 293 cells were transfected with 600 ng of *tkD2A-Luc* (*upper left panel*) or *mFli-1-(–270/–41)-Luc* (*upper right panel*) reporter gene together with 150 ng of *FLI-1* and increasing amounts of *ARIP3* as indicated. Cells were lysed after 24 h, and extracts were assayed for luciferase activity. The *lower panels* represent the whole cell lysate subjected to SDS-PAGE and Western blotting to verify the expression of *FLI-1* using anti-*FLI-1* antibody and increasing amounts of *ARIP3* using anti-*ARIP3* antibody. *Error bars* represent the S.D. of at least three independent experiments. B, 293 cells were transfected with the *tkD2A-Luc* reporter gene together with the indicated amounts of expression plasmid encoding either *wtFLI-1* or the sumoylation-defective *FLI-1*(K67R) mutant. C, 293 cells were transfected with the *tkD2A-Luc* reporter gene (*600 ng*) together with a fixed amount (*150 ng*) of *FLI-1* expression vector with or without the indicated amounts of the *ARIP3* expression plasmid. Cells were harvested 24 h after transfection, and luciferase content was assessed as described under "Experimental Procedures." The effect of *ARIP3* on *FLI-1* transactivation is shown relative to *FLI-1* or *FLI-1*(K67R) transactivation without *ARIP3*, which was put at 100%. *Error bars* represent the S.D. of at least three independent experiments. D, 293 cells were transfected with the *tkD2A-Luc* reporter gene together with the expression plasmid for *wtFLI-1* and increasing amounts of *wtARIP3*, *ARIP3*-(*Δ347*–418), or *ARIP3*(W383A) as indicated. Cells were harvested 24 h after transfection, and luciferase activity in cell extracts was assessed as described under "Experimental Procedures." *Error bars* represent the S.D. of at least three independent experiments. In A–C, -fold activation was calculated as the increase in luciferase activity induced by coexpressed *FLI-1* and *ARIP3* proteins compared with basal reporter gene activity. *a.u.*, arbitrary units.

contrast, *ARIP3* localized to nuclear speckles (Fig. 6A), in agreement with previous studies (23). Similar results were obtained in HeLa cells (data not shown). Strikingly, coexpression of *ARIP3* and *FLI-1* led to a partial relocalization of *FLI-1* to *ARIP3* nuclear bodies (Fig. 6A). Relocalization is independent of *FLI-1* sumoylation, as the non-sumoylation-able *FLI-1*(K67R) mutant also relocalized to *ARIP3* nuclear bodies upon coexpression with *ARIP3* (Fig. 6A). Because an intact SAP domain in *ARIP3* is essential for its ability to interact physically with *FLI-1*, we analyzed the ability of *ARIP3*-(*Δ*13–28) to relocalize *FLI-1*. Interestingly, *ARIP3*-(*Δ*13–28) displayed a different pattern of nuclear body formation compared with *wtARIP3*, forming a small number of larger structures (*2*–*15/nucleus*) (Fig. 6B). Unlike *wtARIP3*, *ARIP3*-(*Δ*13–28) failed to relocalize *FLI-1* to nuclear bodies, indicating that the integrity of the SAP domain is essential to the ability of *ARIP3* to sequester *FLI-1* into nuclear bodies (Fig. 6B). Deletion of amino acids *467*–*487* (the SUMO-binding region of *ARIP3*), which leads to the formation of fewer nuclear dots (23) and to partial cytoplasmic localization of *ARIP3*, also relocalized *FLI-1* to nuclear dots (Fig. 6B). This indicates that relocalization of *FLI-1* to *ARIP3* nuclear bodies is independent of SUMO binding to *ARIP3*. As described previously for *ARIP3* and other PIAS family

members (23, 31), E3-deficient mutants of *ARIP3*, viz. *ARIP3*-(*Δ*347–418) and *ARIP3*(W383A), displayed a diffuse nuclear localization. Coexpression of *FLI-1* with either *ARIP3*-(*Δ*347–418) or *ARIP3*(W383A) did not change the diffuse pattern normally seen with *FLI-1* (Fig. 6B). Because these mutants efficiently bound *FLI-1* and repressed *FLI-1* transcriptional activation properties, *ARIP3*-mediated relocalization of *FLI-1* to nuclear bodies does not seem to be sufficient to explain its ability to functionally repress *FLI-1*.

*ARIP3 Does Not Inhibit FLI-1 DNA-binding Activity*—The mapping studies described above indicated that the ETS domain of *FLI-1* is sufficient to interact physically with *ARIP3*. It is therefore possible that the inhibitory properties of *ARIP3* result from its ability to impair the DNA-binding activity of *FLI-1* for EBS sequences. The specific DNA-binding activity of *FLI-1* for an optimal EBS oligonucleotide was not inhibited when performed in the presence of excess recombinant *ARIP3*, as analyzed by electrophoretic mobility shift assay (data not shown). To further demonstrate that the binding of *FLI-1* is compatible with complex formation with *ARIP3*, the specific DNA-binding activity of *FLI-1* was assayed by oligonucleotide pull-down assay using a biotinylated double-stranded EBS oligonucleotide immobilized on streptavidin beads and
FLI-1 Functionally Interacts with PIASxα

<figure><img src="image_7.png" /><figcaption>FIGURE 6. FLI-1 relocalizes to ARIP3 nuclear bodies. A and B, 293 cells grown on coverslips were transfected with expression plasmids encoding the indicated proteins. 48 h after transfection, cells were fixed with paraformaldehyde and stained with anti-FLI-1 antibody/fluorescein isothiocyanate (FITC)-conjugated anti-rabbit IgG to detect FLI-1 (green), anti-FLAG antibody/Texas Red (Tet RED)-coupled anti-rabbit IgG to detect ARIP3 (red), or Hoechst dye as described under "Experimental Procedures." Images were obtained as described under "Experimental Procedures," and merged image overlaps were obtained using MetaMorph software. Additional processing of images was performed using Adobe Photoshop software.</figcaption></figure>

cell extracts in which HA-FLI-1 was expressed in the presence or absence of HA-ARIP3 (Fig. 7A). FLI-1 was efficiently bound by the EBS oligonucleotide affinity matrix as analyzed by Western blotting (Fig. 7B, lane 2). This binding was specific because DNA binding by FLI-1 was not observed using streptavidin beads loaded with a mutated EBS oligonucleotide as an affinity matrix (Fig. 7B, lanes 2 and 5). Notably, in extracts coexpressing HA-FLI-1 and HA-ARIP3, HA-ARIP3 was also specifically recovered from the wtEBS affinity matrix, showing that formation of the FLI-1·ARIP3 complex did not interfere with the DNA-binding activity of FLI-1 (Fig. 7B, lanes 2 and 6).

The Interaction between FLI-1 and ARIP3 Is Essential for the Repres-
sive Function of ARIP3 in FLI-1 Transactivation—To analyze whether
the inhibitory properties of ARIP3 are linked to its ability to physically
interact with FLI-1, we analyzed the effect of a series of ARIP3 deletion
mutants that either maintained or did not maintain their ability to inter-
act with FLI-1 (Fig. 2) (data not shown) on FLI-1-mediated transactiva-
tion. Fig. 8A shows that the SAP domain of ARIP3, which is required for
the physical interaction between FLI-1 and ARIP3, is also critical for the
transcriptional inhibitory properties of ARIP3 because both ARIP3-
(Δ1–102) and ARIP3-(Δ13–28) failed to inhibit FLI-1 transactivation
properties. In contrast, ARIP3-(Δ102–207), ARIP3-(Δ102–260),
ARIP3-(Δ198–337), and ARIP3-(Δ467–547), which associated with
FLI-1 *in vivo* and *in vitro*, also fully inhibited FLI-1-mediated transacti-
vation. Together with the data of Fig. 5D, these results show that the
region of ARIP3 extending from amino acids 102 to 418 is not critical to
ARIP3 inhibitory properties and that ARIP3-mediated inhibition of
FLI-1 activity is linked to the ability of ARIP3 to physically bind FLI-1.
Mutant ARIP3-(Δ346–475) displayed a reduced ability to repress
FLI-1. However, this protein only partially localized to the nucleus (data
not shown), suggesting that the diminished inhibitory activity of this
mutant is not intrinsic, but results from its incomplete accumulation in
the nucleus. Of note, equal expression of FLI-1 was observed under the
different conditions tested (Fig. 8B, lower panel).

DISCUSSION

In this study, several components of the post-translational sumoyla-
tion pathway have been identified in a yeast two-hybrid screen as inter-
actors of FLI-1, including SUMO-1 itself; Ubc9, the E2 enzyme involved
in the conjugation of SUMO to the ε-amino group of specific lysines in
protein substrates; and PIASxα, one of the E3 ligases that facilitate

SUMO conjugation to specific substrates. An interaction between FLI-1
and Ubc9 has previously been reported (33), but no link was established
to either FLI-1 sumoylation or regulation of FLI-1 transcriptional activ-
ity. We report here that (i) FLI-1 is sumoylated *in vitro* by recombinant
Ubc9 and *in vivo* at a single lysine residue at position 67, which is part of
a classical φKXE Ubc9-binding site located in its transcriptional activa-
tion domain; (ii) FLI-1 binds through its ETS domain to PIASxα, and the
integrity of the SAP domain of PIASxα is required for this interaction;
and (iii) the interaction of FLI-1 with PIASxα enhances FLI-1 sumoyla-
tion at Lys⁶⁷, represses FLI-1 transcriptional activation properties, and
leads to the sequestering of FLI-1 into PIASxα nuclear bodies.

PIAS proteins were first identified as repressors of the DNA-binding activity of tyrosine-phosphorylated STAT proteins, with PIAS1 and PIAS3 being specific to STAT1 and STAT3, respectively (34, 35). Later, PIASx and PIASy were shown to inhibit STAT4 and STAT1 transcriptional activity, respectively, without interfering with DNA binding (36, 37). Recent studies with *pias1*-deficient cells have shown, however, that PIAS1 interfering activity is specific to a small subset of STAT1 target genes critical to the interferon-β- and interferon-γ-mediated innate immune responses (38). PIAS transcriptional regulatory properties are not limited to activated STAT proteins, as they have been found to regulate positively or negatively, through ill defined mechanisms, the activity of other transcription factors, e.g. members of the nuclear receptor superfamily (for review, see Ref. 17). All members of the PIAS family have been shown to be SUMO E3 ligases that can favor sumoylation of a number of DNA-binding transcriptional regulators and co-regulators (for review, see Ref. 17). Gene inactivation of Siz1 and Siz2, the PIAS homologs in yeast, results in reduction in global protein sumoylation (39), and the *Drosophila* melanogaster PIAS homolog SU(VAR)2-10 is required for viability. In contrast, gene inactivation of PIASx, PIAS1, or PIASy by homologous recombination in mouse cells has no discernible effect on global protein sumoylation and is viable, indicating that PIAS proteins are likely to be redundant in mammals (38, 40–42). Our *in vitro* and *in vivo* experiments have shown that FLI-1 conjugation to SUMO-1 is specifically enhanced by PIASxα/ARIP3 and its spliced variant PIASxβ, but much less efficiently by PIAS1 and not at all by PIASy and PIAS3, indicating a clear selectivity for specific members of the PIAS family. The reduced activity of PIAS1 does not reflect a failure to interact with FLI-1 because FLI-1 and PIAS1 were found to physically
FLI-1 Functionally Interacts with PIASxα

<figure><img src="image_8.png" /></figure>

FIGURE 7. FLI-1 binding to ETS-binding sequences is not inhibited by ARIP3. A, shown are the results from expression analysis of FLI-1 and ARIP3 in the whole cell extracts used in B. 293 cells were transfected with vectors encoding HA-FLI-1 alone or with HA-ARIP3, lysed after 48 h as described under "Experimental Procedures," and subjected to SDS-PAGE and Western blotting. Blots were stained with anti-HA antibody to detect HA-FLI-1 and HA-ARIP3. B, the 293 lysates described for A containing FLI-1 and/or ARIP3 were subjected as indicated to oligonucleotide pull-down assay using, as an affinity matrix, either biotinylated wtEBS or mutant EBS (m-EBS) carrying a GG-to-CC transition in its core. Briefly, lysates were incubated with biotinylated wtEBS or mutant EBS double-stranded oligonucleotides immobilized on streptavidin beads. Bound proteins were analyzed by SDS-PAGE and Western blotting using anti-HA (upper panel) and anti-ARIP3 (lower panel) antibodies. C, unbound proteins in the oligonucleotide pull-down assay described for B were resolved by SDS-PAGE and Western blotting using anti-HA antibody to stain for HA-FLI-1 and HA-ARIP3. Both FLI-1 and ARIP3 were present in this fraction, indicating that the experiment was performed under equilibrium conditions. Arrows indicate the different proteins, and asterisks indicate the presence of a nonspecific background band. WCL, whole cell lysate.

interact when coexpressed *in vivo*,<fnref n="5" /> suggesting that FLI-1 is preferen-
tially modified by PIASx proteins.

PIASxα/ARIP3 acts as a repressor of FLI-1-dependent EBS-driven
transcription. SUMO modification of DNA-bound transcription fac-
tors often targets known repression domains and can result in enhanced
repression (for review, see Ref. 17; Ref. 43). Although the SUMO target
(Lys⁶⁷) is located in the N-terminal activation domain of FLI-1, two lines
of evidence indicate that enhanced FLI-1 sumoylation is not involved in
PIASxα-mediated transcriptional repression. First, FLI-1(K67R), in
which Lys⁶⁷ has been replaced with a non-sumoylatable arginine,
although similarly effective in transactivation compared with wtFLI-1,
was as efficiently repressed by PIASxα/ARIP3 as was wtFLI-1. Second,
despite the fact that the closely related splice variant PIASxβ activated
FLI-1 sumoylation as efficiently as PIASxα, it failed to inhibit FLI-1-
mediated EBS-driven transcription. This situation is not unprecedented
because repression of, for example, the transcriptional activity of LEF-1
by PIASy is also unlinked to its PIASy-mediated sumoylation at specific
lysine residues (31). Interestingly, RING finger mutants of PIASxα/
ARIP3 that are deficient in SUMO conjugation, viz. ARIP3(W383A) and
ARIP3-(Δ347–418), fully repressed FLI-1 transactivation, indicating

that regulatory sumoylation of known FLI-1 coactivators such as p300
(13, 44) or corepressors is not critically involved in the repressive actions
of PIASxα on FLI-1. Other transcription factors, including GATA-2 and
the androgen receptor, are also repressed by PIAS family members inde-
pendent of an active RING domain (45–47), but the molecular mecha-
nisms involved remain to be characterized.

PIASxα/ARIP3 and other PIAS proteins are localized in nuclear bod-
ies of largely unknown composition and function, but may partially
overlap with promyelocytic leukemia nuclear bodies (23, 31). The asso-
ciation of PIAS proteins with nuclear bodies appears to require their
SUMO ligase activity because ligase-deficient PIAS mutants are unable
to assemble into PIAS bodies (31, 45). Binding of PIASxα/ARIP3 to
other sumoylated proteins and its targeting to the nuclear matrix also
seem to be required for the formation of typical PIASxα bodies because
deletion of the SUMO-1-binding motif of PIASxα/ARIP3 (amino acids
467–487) and deletion of the matrix/scaffold attachment region target-
ing the SAP domain both impair the formation of normal PIASxα/
ARIP3 nuclear bodies (Fig. 6) (23). Our data show that ARIP3 relocalizes
the normally diffusely distributed FLI-1 protein from the nucleoplasm
to PIASxα/ARIP3 nuclear bodies, suggesting that repression of FLI-1
could result from its relocalization to PIASxα bodies. However, because
FLI-1 remains diffusely distributed in the nucleoplasm in cells coex-
pressing FLI-1 and the ligase-deficient PIASxα/ARIP3 mutants and
because these mutants repress FLI-1-mediated transcription and inter-
act with FLI-1 as efficiently as wtPIASxα, it appears that relocalization
of FLI-1 to PIASxα nuclear bodies is not mandatory for ARIP3 to repress
FLI-1 activity. However, relocalization of FLI-1 to PIASxα/ARIP3
nuclear bodies could stabilize the inhibitory complex. Relocalization of
FLI-1 to nuclear bodies is also independent of FLI-1 sumoylation
because the sumoylation-deficient FLI-1(K67R) mutant relocalized to
PIASxα bodies when coexpressed with PIASxα/ARIP3 in a fashion
indistinguishable from wtFLI-1. The SAP domain of PIAS proteins
binds AT-rich matrix/scaffold attachment region sequences *in vitro* (31,
32), and both PIASxα/ARIP3 and ligase-deficient mutants of PIASxα
have been found to associate with detergent-insoluble nuclear fractions
in a manner dependent upon their SAP domain.<fnref n="5" /> It is therefore possible
that, although recruitment of FLI-1 to mature PIASxα nuclear bodies is
not instrumental in its inhibition, its targeting to the nuclear matrix
could be important. A proper answer to this question will require the
design of SAP domain mutations that dissociate the matrix/scaffold
attachment region-targeting activity of PIASxα from its binding activity
for FLI-1.

By what mechanism does PIASxα repress FLI-1 transcriptional activ-
ity? The isolated ETS domain of FLI-1 is sufficient to bind PIASxα/
ARIP3, yet PIASxα failed to inhibit the specific binding of FLI-1 to
canonical DNA response elements *in vitro*, suggesting that inhibition
does not occur at the level of DNA binding. Our mutant studies have
shown that PIASxα-mediated repression correlates with physical com-
plex formation between FLI-1 and PIASxα. A small deletion in the SAP
domain of PIASxα suppressed both PIASxα/ARIP3 repressive activity
and complex formation with FLI-1, whereas mutations in other
domains of PIASxα affected neither repression nor binding to FLI-1.
Complex formation between FLI-1 and PIASxα could result in masking
of the FLI-1 activation domain, thereby competing for the recruitment
of coactivators. We do not favor this notion because EWS-FLI-1-medi-
ated EBS-dependent transactivation, which relies entirely on a structur-
ally unrelated, EWS-derived activation domain (20), was also inhibited
by PIASxα/ARIP3.<fnref n="5" /> Previous analyses have shown that transcriptional
repression of the androgen receptor by PIASy and of STAT4 by PIASxα
involves the recruitment of histone deacetylase or histone deacetylase-

<footnote n="5">⁵ E. van den Akker, S. Ano, and J. Ghysdael, unpublished data.</footnote>
FLI-1 Functionally Interacts with PIASxα

<figure><img src="image_9.png" /></figure>

FIGURE 8. ARIP3-induced repression of FLI-1 transactivation is dependent on the integrity of the SAP domain. A, 293 cells were transfected with the tkD2A-Luc reporter gene (600 ng) and ΔEB-FLI-1 (150 ng) in the absence (tpo) or presence of pFLAG-wtARIP3 (250 ng) or the indicated ARIP3 deletion mutants. The luciferase activities in the corresponding cell extracts are shown as black bars. The white bars indicate the tkD2A-Luc reporter activity when no ΔEB-FLI-1 was present. -Fold activation was calculated as the increase in reporter gene activity compared with basal reporter gene activity (bar 2). To account for differences in expression levels between ARIP3 and the different mutants derived thereof, the ratio between the expression levels of wtARIP3 and its mutants was used to normalize the transactivation values (see below). Error bars represent the S.D. of at least three independent experiments. B, an aliquot of the pooled lysates from the transactivation experiment described for A was subjected to SDS-PAGE and Western blotting to assess the expression levels of wtARIP3 and ARIP3 deletion mutants (anti-FLAG antibody; upper panel) and FLI-1 (anti-FLI-1 antibody; lower panel) in the different samples. The expression levels were measured by quantification of luminescence using GeneSnap/GeneTools software. The relative expression ratios of the different ARIP3 mutants compared with wtARIP3 (A3/MUT) are indicated and were used to normalize the luciferase activity values. a.u., arbitrary units; WCL, whole cell lysate.

associated corepressors (36, 47). We found PIASxα-mediated repre-
sion of FLI-1 to be insensitive to trichostatin A,⁵ suggesting that the
members of the class I and II histone deacetylase families are unlikely to
be involved in PIASxα-mediated repression of FLI-1. PIASxα and
PIASxβ are isoforms with similar primary amino acid sequences, except
that the unique C-terminal 71 amino acids in PIASxα are replaced with
an unrelated sequence of 122 amino acids in PIASxβ. In our experimen-
tal setting, only PIASxα acted as repressor for FLI-1,⁵ suggesting either
a direct role for the unique C-terminal domain of PIASxα in repression
or an unknown role of the C-terminal domain of PIASxβ in preventing
PIASx repressive activity. Experiments are in progress to compare the
cofactors that associate with the repressive FLI-1-PIASxα complex in a
manner dependent upon the unique C-terminal domain of PIASxα.

Our results did not identify any functional consequences of SUMO
conjugation to FLI-1. It should be noted, however, that FLI-1 sumoyla-
tion occurs at low stoichiometry *in vivo* and could have functional con-
sequences in a compartmentalized fashion. In accordance with the
transportable repressive properties of SUMO-1 (45), the experimental
covalent fusion of SUMO-1 to the N terminus of FLI-1 converted FLI-1
from a transcriptional activator into a repressor of EBS-mediated tran-
scription,⁵ suggesting that stoichiometric sumoylation of FLI-1 could be
repressive. Furthermore, the functional consequences of sumoylation
on several DNA-binding transcriptional regulators have been shown to
depend upon the promoter context (18, 32). In this respect, like other
members of the ETS family, FLI-1 functions in close synergy with other
cis-bound DNA-binding cofactors, often on composite DNA response
elements, to regulate transcriptional output. For example, in line with
the requirement of FLI-1 in megakaryocytic development and differen-
tiation (1–3), the promoters of a number of megakaryocytic lineage-
specific genes contain closely juxtaposed binding sites for FLI-1 and
GATA-1, a configuration that is instrumental in their developmentally
regulated expression (6, 48). It is therefore possible that recruitment of
the sumoylation machinery to specific promoters and sumoylation of
cooperating cis-bound factors are important in regulating the transcrip-
tional synergy in a promoter- and cell context-specific manner.

In conclusion, we have identified PIASxα as a novel repressor of FLI-1 and FLI-1-derived oncoproteins; PIASxα impairs FLI-1 transcriptional activity and sequesters FLI-1 into nuclear bodies. Interestingly, repre-
sion by PIASxα is independent of its SUMO ligase activity and of FLI-1

sumoylation, but depends upon the physical interaction between FLI-1
and PIASxα. The activity of FLI-1 may be repressed first through the
assembly of corepressors complexes at the chromatin level and target-
ing of the FLI-1-PIASxα complex to the nuclear matrix, followed by final
assembly into mature PIASxα nuclear bodies.

REFERENCES

1. Hart, A., Melet, F., Grossfeld, P., Chien, K., Jones, C., Tunnacliffe, A., Favier, R., and Bernstein, A. (2000) *Immunity* **13**, 167–177

2. Spyropoulos, D. D., Pharr, P. N., Lavenburg, K. R., Jackers, P., Papas, T. S., Ogawa, M., and Watson, D. K. (2000) *Mol. Cell. Biol.* **20**, 5643–5652

3. Kawada, H., Ito, T., Pharr, P. N., Spyropoulos, D. D., Watson, D. K., and Ogawa, M. (2001) *Int. J. Hematol.* **73**, 463–468

4. Masuya, M., Moussa, O., Abe, T., Deguchi, T., Higuchi, T., Ebihara, Y., Spyropoulos, D. D., Watson, D. K., and Ogawa, M. (2005) *Blood* **105**, 95–102

5. Truong, A. H., and Ben-David, Y. (2000) *Oncogene* **19**, 6482–6489

6. Eisbacher, M., Holmes, M. L., Newton, A., Hogg, P. J., Khachigian, L. M., Crossley, M., and Chong, B. H. (2003) *Mol. Cell. Biol.* **23**, 3427–3441

7. Czuwara-Ladykowska, J., Shirasaki, F., Jackers, P., Watson, D. K., and Trojanowska, M. (2001) *J. Biol. Chem.* **276**, 20839–20848

8. Tamir, A., Howard, J., Higgins, R. R., Li, Y. J., Berger, L., Zacksenhaus, E., Reis, M., and Ben-David, Y. (1999) *Mol. Cell. Biol.* **19**, 4452–4464

9. Darby, T. G., Meissner, J. D., Ruhlmann, A., Mueller, W. H., and Scheibe, R. J. (1997) *Oncogene* **15**, 3067–3082

10. Starck, J., Cohet, N., Gonnet, C., Sarrazin, S., Doubeikovskaia, Z., Doubeikovski, A., Verger, A., Duterque-Coquillaud, M., and Morle, F. (2003) *Mol. Cell. Biol.* **23**, 1390–1402

11. Pereira, R., Quang, C. T., Lesault, I., Dolznig, H., Beug, H., and Ghysdael, J. (1999) *Oncogene* **18**, 1597–1608

12. Lesault, I., Quang, C. T., Frampton, J., and Ghysdael, J. (2002) *EMBO J.* **21**, 694–703

13. Ano, S., Pereira, R., Pironen, M., Lesault, I., Milley, C., Lebigot, I., Quang, C. T., and Ghysdael, J. (2004) *J. Biol. Chem.* **279**, 2993–3002

14. Lebigot, I., Gardellin, P., Lefebvre, L., Beug, H., Ghysdael, J., and Quang, C. T. (2003) *Blood* **102**, 4555–4562

15. Arvand, A., Welford, S. M., Teitell, M. A., and Denny, C. T. (2001) *Cancer Res.* **61**, 5311–5317

16. Stein, G. S., van Wijnen, A. J., Stein, J. L., Lian, J. B., Pockwinse, S. M., and McNeil, S. (1998) *J. Cell. Biochem. Suppl.* **30–31**, 220–231

17. Seeler, J. S., and Dejean, A. (2003) *Nat. Rev. Mol. Cell. Biol.* **4**, 690–699

18. Moilanen, A. M., Karvonen, U., Poukka, H., Yan, W., Toppari, J., Janne, O. A., and Palvimo, J. J. (1999) *J. Biol. Chem.* **274**, 3700–3704

19. Gyuris, J., Golemis, E., Chertkov, H., and Brent, R. (1993) *Cell* **75**, 791–803

20. Bailly, R. A., Bosselut, R., Zucman, J., Cormier, F., Delattre, O., Roussel, M., Thomas, G., and Ghysdael, J. (1994) *Mol. Cell. Biol.* **14**, 3230–3241

21. Rabault, B., and Ghysdael, J. (1994) *J. Biol. Chem.* **269**, 28143–28151

22. Muller, S., Berger, M., Lehembre, F., Seeler, J. S., Haupt, Y., and Dejean, A. (2000) *J. Biol. Chem.* **275**, 13321–13329

<figure><img src="image_10.png" /></figure>
FLI-1 Functionally Interacts with PIASα

23. Kotaja, N., Karvonen, U., Janne, O. A., and Palvimo, J. J. (2002) *Mol. Cell. Biol.* **22**, 5222–5234

24. Kotaja, N., Vihinen, M., Palvimo, J. J., and Janne, O. A. (2002) *J. Biol. Chem.* **277**, 17781–17788

25. van den Akker, E., van Dijk, T. B., Parren-van Amelsvoort, M. P., Grossmann, K. S., Schaeper, U., Toney-Earley, K., Waltz, S. E., Lowenberg, B., and von Lindern, M. (2004) *Blood* **103**, 4457–4465

26. van Dijk, T. B., van den Akker, E., Amelsvoort, M. P., Mano, H., Lowenberg, B., and von Lindern, M. (2000) *Blood* **96**, 3406–3413

27. Kirsh, O., Seeler, J. S., Pichler, A., Gast, A., Muller, S., Miska, E., Mathieu, M., Harel-Bellan, A., Kouzarides, T., Melchior, F., and Dejean, A. (2002) *EMBO J.* **21**, 2682–2691

28. de Boer, E., Rodriguez, P., Bonte, E., Krijgsveld, J., Katsantoni, E., Heck, A., Grosveld, F., and Strouboulis, J. (2003) *Proc. Natl. Acad. Sci. U. S. A.* **100**, 7480–7485

29. Nishida, T., and Yasuda, H. (2002) *J. Biol. Chem.* **277**, 41311–41317

30. Starck, J., Mouchiroud, G., Gonnet, C., Mehlen, A., Aubert, D., Dorier, A., Godet, J., and Morle, F. (1999) *Exp. Hematol.* **27**, 630–641

31. Sachdev, S., Bruhn, L., Sieber, H., Pichler, A., Melchior, F., and Grosschedl, R. (2001) *Genes Dev.* **15**, 3088–3103

32. Tan, J. A., Hall, S. H., Hamil, K. G., Grossman, G., Petrusz, P., and French, F. S. (2002) *J. Biol. Chem.* **277**, 16993–17001

33. Hahn, S. L., Wasylyk, B., and Criqui-Filipe, P. (1997) *Oncogene* **15**, 1489–1495

34. Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., and Shuai, K. (1997) *Science* **278**, 1803–1805

35. Liu, B., Liao, J., Rao, X., Kushner, S. A., Chung, C. D., Chang, D. D., and Shuai, K. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 10626–10631

36. Arora, T., Liu, B., He, H., Kim, J., Murphy, T. L., Murphy, K. M., Modlin, R. L., and Shuai, K. (2003) *J. Biol. Chem.* **278**, 21327–21330

37. Liu, B., Gross, M., ten Hoeve, J., and Shuai, K. (2001) *Proc. Natl. Acad. Sci. U. S. A.* **98**, 3203–3207

38. Liu, B., Mink, S., Wong, K. A., Stein, N., Getman, C., Dempsey, P. W., Wu, H., and Shuai, K. (2004) *Nat. Immunol.* **5**, 891–898

39. Johnson, E. S., and Gupta, A. A. (2001) *Cell* **106**, 735–744

40. Roth, W., Sustmann, C., Kieslinger, M., Gilmozzi, A., Irmer, D., Kremmer, E., Turck, C., and Grosschedl, R. (2004) *J. Immunol.* **173**, 6189–6199

41. Wong, K. A., Kim, R., Christofk, H., Gao, J., Lawson, G., and Wu, H. (2004) *Mol. Cell. Biol.* **24**, 5577–5586

42. Santti, H., Mikkonen, L., Anand, A., Hirvonen-Santti, S., Toppari, J., Panhuysen, M., Vauti, F., Perera, M., Corte, G., Wurst, W., Janne, O. A., and Palvimo, J. J. (2005) *J. Mol. Endocrinol.* **34**, 645–654

43. Johnson, E. S. (2004) *Annu. Rev. Biochem.* **73**, 355–382

44. Girdwood, D., Bumpass, D., Vaughan, O. A., Thain, A., Anderson, L. A., Snowden, A. W., Garcia-Wilson, E., Perkins, N. D., and Hay, R. T. (2003) *Mol. Cell* **11**, 1043–1054

45. Ungureanu, D., Vanhatupa, S., Kotaja, N., Yang, J., Aittomaki, S., Janne, O. A., Palvimo, J. J., and Silvennoinen, O. (2003) *Blood* **102**, 3311–3313

46. Chun, T. H., Itoh, H., Subramanian, L., Iniguez-Lluhi, J. A., and Nakao, K. (2003) *Circ. Res.* **92**, 1201–1208

47. Gross, M., Yang, R., Top, I., Gasper, C., and Shuai, K. (2004) *Oncogene* **23**, 3059–3066

48. Lemarchandel, V., Ghysdael, J., Mignotte, V., Rahuel, C., and Romeo, P. H. (1993) *Mol. Cell. Biol.* **13**, 668–676